Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:20 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer
NCT05442749 · Centre Leon Berard · PHASE2 · terminated · last registry update 2026-02-17 · Pancreatic cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study not feasible, patient accrual rate too low.” | – | Registry record, Centre Leon Berard |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PARP2 in pancreatic cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-04Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Nab-paclitaxel + Gemcitabine (NCT04753879)
- 2026-08-14Also stopped (terminated): National Cancer Institute (NCI), Olaparib (NCT05286827)
- 2026-05-19Results posted on the registry: National Cancer Institute (NCI), Cisplatin + Gemcitabine (NCT01585805)
- 2026-03-11Results posted on the registry: National Cancer Institute (NCI), Olaparib (NCT05286827)
- 2025-12-01Also stopped (terminated): Gustave Roussy, Cancer Campus, Grand Paris, Dostarlimab + Niraparib (NCT04779151)
- 2025-11-06Results posted on the registry: Georgetown University, ABT-888 + mFOLFOX-6 (NCT01489865)
- 2025-11-06Also stopped (terminated): Nuvation Bio Inc., NUV-868 + Olaparib (NCT05252390)
- 2025-10-29Results posted on the registry: Tempus AI, Niraparib (NCT05169437)
- 2025-10-29Also stopped (terminated): Tempus AI, Niraparib (NCT05169437)
- 2025-08-07Results posted on the registry: Mayo Clinic, Dostarlimab + Niraparib (NCT04493060)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision